Introducing CAPAC

Next Generation Tumor Targeting

Over the past decade, antibody-drug conjugates have transformed tumor-targeted drug delivery and activation.But a fixed drug antibody ratio and the need for a linker hamper the ability to optimize safety and efficacy, and this has meant persistent toxicity issues.

The ideal ADC is just an antigen targeting agent and an effective payload. This is CAPAC.

CAPAC uses click chemistry to activate cancer drugs at the tumor.

Our payloads have highly attenuated activity and plasma stability until they click with tumor targeting activators. This minimizes off-target effects.Using chemistry for targeting and activation means internalization is not needed, expanding possible targets.

We can use monoclonal antibodies, anti-body fragments, VHH, or peptides for tumor targeting, and pair these with payloads of including chemotherapy, highly toxic agents and immune agonists.

Separating Payload from Tumor Targeting Changes Everything.

Separation of the the payload and tumor targeting agent creates flexibility and unprecedented tunabilty. Both the tumor targeting activator and the payload can be titrated to optimize safety and efficacy throughout development, including in the clinic. 

CAPAC clinically validated

We have validated the CAPAC platform and demonstrated proof of concept with our most advanced asset, SQ3370. This pairs a tumor-injected biopolymer loaded with a click component, which activates a doxorubicin protodrug which is administered systematically.

In our phase 1 study, SQ3370 was well-tolerated with no dose-limiting toxicities, even in patients receiving >15x the conventional dose-equivalent of doxorubicin per cycle.

Our pipeline

We are building a diverse pipeline of tumor targeting activators and payloads and have exciting preclinical data validating our approach. 

Key data:SQP22: A HER2 targeted MMAE protodrug that shows strong anti-tumor effect and superiority over disitamab vedotin

SQP07Description: a single dose of an exatecan protodrug causes complete tumor regression with a single dose